AYURCANN REPORTS FISCAL YEAR 2025 RECORD SALES OF $55,446,352 IN GROSS REVENUE, FEATURING 21% YEAR-OVER-YEAR INCREASE AND PROVIDES CORPORATE UPDATE

Toronto, Ontario, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR; OTCQB: AYURF) (“Ayurcann” or the “Company”), a leading Canadian processing and manufacturing company specializing in cannabis 2.0 and 3.0 products, is pleased to announce its financial and operational results for the year ended June 30, 2025, the highlights of which are included in this news release. All figures are reported in Canadian dollars. The Company’s full set of consolidated audited financial statements for the years ended June 30, 2025 and 2024 and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.ayurcann.com and its profile page on SEDAR+ at www.sedarplus.ca.

AYURCANN: A LEADING FORCE IN CANADIAN CANNABIS

Ayurcann continues to cement its position as one of the country’s most resilient cannabis companies. Since entering the market in 2020, Ayurcann has delivered exceptional performance, and growth for the past four fiscal years, growing 100% year-over-year in sales for the past 3 fiscal years (2021-2024) — a testament to its disciplined strategy, operational strength, and market leadership.

POWERFUL NATIONAL PRESENCE

Ayurcann’s products are now available in over 75% of licensed retail cannabis stores² across Canada, representing a truly national footprint. This expansive distribution network has been a major driver of the Company’s rapid growth, ensuring its brands are accessible to consumers coast-to-coast and positioning Ayurcann as a trusted partner among retailers nationwide.

DOMINANT IN ONTARIO: CANADA’S LARGEST MARKET

In Ontario — the largest cannabis market in Canada² — Ayurcann’s leadership is unmatched. The Company has achieved over 80% retail penetration², with products carried in more than 1,500 licensed stores² across the province. Strong relationships with the Ontario Cannabis Store and retail partners have enabled Ayurcann to capture significant market share.

FINANCIAL HIGHLIGHTS – FISCAL YEAR ENDED JUNE 30, 2025

Gross Revenue: $55,446,352 for the fiscal year ended June 30, 2025 (vs. $45,265,235 in 2024)

Adjusted EBITDA¹: $507,570 for the period (vs. -$352,492 in FY2024)

Product Portfolio: Expanded to 80 SKUs nationwide

“As the cannabis industry continues to mature in Canada, we are thrilled to see sustained growth and strong demand for our brands across multiple provinces,” said Igal Sudman, Chief Executive Officer of Ayurcann. “Despite price compression and competitive pressures, our focus on the business-to-consumer market has enabled Ayurcann to expand market share, diversify product offerings, and strengthen brand loyalty nationwide.”

OPERATIONAL HIGHLIGHTS – FISCAL YEAR 2025

Over 35,500 product listings² across dispensaries in Ontario, New Brunswick, Manitoba, Saskatchewan, Alberta, British Columbia, Newfoundland, and Yukon

Ongoing innovation and new product development, reinforcing Ayurcann’s reliability

Strong consumer demand across vape, concentrate and flower categories

Continued investment in operational efficiency, supply chain optimization and production scalability

“Our continued success is rooted in innovation, reliability, and our ability to anticipate market needs,” added Sudman. “With a clear vision and commitment to excellence, Ayurcann remains focused on driving growth, enhancing shareholder value, and expanding our footprint both domestically and abroad.”

CORPORATE UPDATE

Ayurcann announces that it will voluntarily delist from the OTC Markets Group OTCQB Venture Market (“OTCQB”) effective October 30, 2025. Ayurcann’s shares will continue to trade in Canada on the Canadian Securities Exchange under the current ticker symbol “AYUR”.

For further information, please contact:

Igal Sudman, Chairman and Chief Executive Officer
Ayurcann Holdings Corp.
Tel: 905-492-3322
Email: info@ayurcann.com

Investor Relations:

Email: ir@ayurcann.com

About Ayurcann:

Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is striving to become a partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.

For more information about Ayurcann, please visit www.ayurcann.com and its profile page on SEDAR+ at www.sedarplus.ca.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “strategy”, “expects” or “does not expect”, “intends”, “continues”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “will be taken”, “will launch” or “will be launching”, “will include”, “will allow”, “will be made” “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company meeting its goals and strategic focuses as set out herein; the Company expanding market share, diversifying product offerings and strengthening brand loyalty nationwide; continued investment in operational efficiency, supply chain optimization and production scalability; the Company driving growth, enhancing shareholder value and expanding its footprint domestically and abroad; the Company delisting from the OTCQB; the Company continuing to grow, expand and capitalize on its revenue, sales and growth trajectory; the future growth of the cannabis industry; the Company being well-positioned for long-term growth, profitability, success and providing shareholder returns; and the Company continuing to be a leading player in the cannabis industry.

Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company will have the ability to meet its goals and strategic focuses as set out herein; the Company will expand market share, diversify product offerings and strengthen brand loyalty nationwide; the Company will continue investment in operational efficiency, supply chain optimization and production scalability; the Company will drive growth, enhance shareholder value and expand its footprint domestically and abroad; the Company will delist from the OTCQB; the Company will have the ability to continue to grow, expand and capitalize on its revenue, sales and growth trajectory; cannabis industry will continue to grow; the Company’s will continue to have long-term growth, profitability, success and provide shareholder returns; and the Company will continue to be a leading player in the cannabis industry.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the Company’s inability to meet its goals and strategic focuses as set out herein; the Company’s inability to expand market share, diversify product offerings and/or strengthen brand loyalty nationwide; the Company’s inability to continue investment in operational efficiency, supply chain optimization and/or production scalability; the Company’s inability to drive growth, enhance shareholder value and/or expand its footprint domestically and/or abroad; the Company will stay quoted on the OTCQB; the Company’s inability to continue to grow and capitalize on its revenue and growth trajectory; the Company inability to continue to grow, expand and/or capitalize on its revenue, sales and/or growth trajectory; growth of the cannabis industry declining and/or plateauing; Company growth, profitability and/or shareholder returns declining and/or plateauing; and the Company not being a leading player in the cannabis industry.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed under the heading “Risk Factors” in the Company’s public disclosure, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at www.sedarplus.ca, which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events, or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

¹ Earnings before interest, taxes, depreciation, and amortization (“EBITDA”) and adjusted EBITDA. These measures do not have a standardized meaning prescribed by International Financial Reporting Standards (“IFRS”) and are, therefore, unlikely to be comparable to similar measures presented by other issuers. Non-IFRS measures provide investors with a supplemental measure of the Company’s operating performance and, therefore, highlight trends in the Company’s core business that may not otherwise be apparent when relying solely on IFRS measures. Management uses non-IFRS measures in measuring the financial performance of the Company.
² As reported by Trellis Insights - June 2025

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.